IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION

CourtDistrict Court, S.D. New York
DecidedDecember 26, 2019
Docket1:19-cv-01578
StatusUnknown

This text of IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION (IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, (S.D.N.Y. 2019).

Opinion

UNITED STATES DISTRICT COURT DATE FILED: 12/26/2 019 SOUTHERN DISTRICT OF NEW YORK -------------------------------------------------------------- X : 19-CV-1578 (VEC) IN RE: NAVIDEA BIOPHARMACEUTICALS : LITIGATION : OPINION AND ORDER X -------------------------------------------------------------- VALERIE CAPRONI, United States District Judge: Plaintiff Navidea Biopharmaceuticals, Inc. (“Navidea”), a pharmaceutical company, sued Michael Goldberg (“Goldberg”) for breach of contract, breach of the covenant of good faith and fair dealing, and breach of fiduciary duty. See Am. Compl., Dkt. 15. Goldberg answered the complaint and asserted counterclaims and third-party claims against Navidea and Third-Party Defendant Macrophage Therapeutics, Inc. (“Macrophage”), a subsidiary of Navidea, for breach of contract, wrongful discharge, injunctive relief, and quantum meruit. Dkt. 31. Goldberg moved to dismiss Plaintiff’s breach of fiduciary duty claim on the grounds that it is time-barred and fails to state a claim. Dkt. 32. Goldberg also seeks advancement of attorneys’ fees in connection with the fiduciary duty claim and Rule 11 sanctions against Plaintiff. Id. Navidea and Third-Party Defendant Macrophage moved to dismiss or strike certain of Goldberg’s counterclaims and third-party claims pursuant to Federal Rules of Civil Procedure 12(b)(1), 12(b)(6), and 12(f). Dkt. 40. Defendant Goldberg’s motion is GRANTED in part and DENIED in part. Plaintiff/Counterclaim Defendant Navidea and Third-Party Defendant Macrophage’s motion is GRANTED. BACKGROUND On August 14, 2018, Navidea, Macrophage, and Goldberg, the former CEO of Navidea and founder of Macrophage, entered into an agreement (the “August Agreement”) with the intent of entering into a further transaction (“the Transaction”) to “provide for the separation of Goldberg from Navidea and the establishment of the parties’ rights and obligations with respect to the ownership, management and continued operations of Macrophage.” Am. Compl., Dkt. 15 ¶ 12. Specifically, and as relevant to the pending motions, the August Agreement provided for: (1) Goldberg’s resignation from Navidea, (2) the sale of 23.5 million shares of Navidea to Goldberg on the date of the consummation of the Transaction; (3) a six-month line of credit from

Navidea to Macrophage of up to $750,000, (4) an issuance to Goldberg of Macrophage Super Voting Common Stock shares in a number equal to 5% of the outstanding shares, and (5) Goldberg’s waiver of all rights to collect any debt owed by Navidea to Goldberg. See August Agreement, Dkt. 31-1. Plaintiff alleges that the future-contemplated agreements have not been executed because Defendant “undertook certain actions which Navidea considered breaches of the August Agreement.” Am. Compl., Dkt. 15 ¶¶ 14, 44-67. Notwithstanding the Plaintiff’s argument, the August Agreement expressly states that “any subsequent failure to execute the Transaction documents shall not render” the Agreement invalid. See August Agreement, Dkt. 31-1.1 a. Defendant’s Opening of the “Secret Account”

On May 8, 2015, Navidea entered into a Term Loan Agreement with Capital Royalty Partners II (“CRG”) for a loan of up to $60,000,000. Am. Compl., Dkt. 15 ¶ 69. Pursuant to the loan agreement, Navidea was required to provide CRG with the control agreements for all depository accounts controlled by either Navidea or Macrophage and to notify CRG of any changes to the deposit accounts. Id. ¶ 71. Failure to provide such notice or control agreements was an event of default under the CRG Loan Agreement. Id.

1 In deciding these motions, the Court may consider the August Agreement, as it is referenced in the complaint and answer and was relied on by both parties in asserting their claims. Chambers v. Time Warner, Inc., 282 F.3d 147, 153 (2d Cir. 2002); see also Brass v. Am. Film Techs., Inc., 987 F.2d 142, 150 (2d Cir. 1993); Cortec Indus., Inc. v. Sum Holding L.P., 949 F.2d 42, 47–48 (2d Cir. 1991); Vtech Holdings Ltd. v. Lucent Techs., Inc., 172 F. Supp. 2d 435, 437 (S.D.N.Y. 2001). On December 1, 2015, allegedly following a rift between Goldberg and other members of Navidea management, Goldberg opened a Wells Fargo account for Macrophage (the “Secret Account”). Id. ¶¶ 72-74. Goldberg failed to inform CRG of the existence of the account and failed to provide CRG with a control agreement, thereby breaching the CRG Loan Agreement.

Id. ¶ 74. CRG ultimately filed suit against Navidea in Texas state court, alleging numerous events of default under the Loan Agreement, including Goldberg’s opening of the Secret Account. Id. ¶ 85. The Texas court entered summary judgment in favor of CRG, concluding that one or more events of default had occurred. Id. ¶ 86. Navidea alleges that, as a result of the summary judgment ruling, it was forced to sell significant assets, resulting in losses exceeding $50 million. Id. ¶¶ 86-91. b. The Platinum Debt Prior to becoming CEO of Navidea, Goldberg had been affiliated with Platinum-Montaur Life Sciences, LLC (“Platinum-Montaur”), a collaboration among Goldberg, Platinum Partners Value Arbitrage Fund LP, Platinum Partners Liquid Opportunity Master Fund L.P., and Platinum

Opportunity (NY) LLC (collectively “Platinum Funds”). Am. Compl., Dkt. 15 ¶ 33. On July 25, 2012, Navidea executed a loan agreement and promissory note (the “Platinum Note”) payable to Platinum-Montaur in an amount of up to $35 million. Navidea and Macrophage Mem. of Law, Dkt. 41 at 4. On November 2, 2017, Platinum-Montaur sued Navidea seeking to recover funds owed by Navidea (the “Platinum Debt”), a part of which Defendant Goldberg asserts he is entitled to.2 Am. Compl., Dkt. 15 ¶¶ 37-38. Goldberg alleges that Platinum assigned him $1.3 million of the Platinum Debt, and that, as of the August Agreement, Navidea owed him $2.5

2 Although the Counterclaim at paragraph 38 asserts that Navidea owes Goldberg money arising from the Platinum Debt, at paragraph 130 Goldberg appears to acknowledge that he released his portion of the Platinum Debt as part of the August Agreement. million (including accrued interest), Counterclaims and Third-Party Claims (CC/TPC), Dkt. 31 ¶¶ 37-38. The August Agreement provided for the issuance of Navidea shares as compensation for Goldberg’s agreement to release his portion of the Platinum Debt. Am. Compl., Dkt. 15 ¶ 39; CC/TPC, Dkt. 31 ¶ 130.

DISCUSSION I. Defendant Goldberg’s Motion to Dismiss Defendant moves to dismiss Plaintiff’s fourth cause of action on the grounds that it is time-barred and fails to state a claim for which relief can be granted. Defendant also seeks attorneys’ fees and Rule 11 sanctions. a. Plaintiff’s Fourth Cause of Action is Dismissed as Time-Barred Plaintiff’s fourth cause of action alleges that Goldberg breached his fiduciary duty of loyalty by “failing to advise Navidea’s board members and management of his decision to open a secret Macrophage bank account in violation of the CRG Loan Agreement and without bothering to consult with Navidea legal counsel.” Am. Compl., Dkt. 15 ¶¶ 120-122. As noted, supra, Navidea and CRG entered into a Loan Agreement pursuant to which Navidea was required to provide CRG with the control agreements for all depository accounts controlled by Navidea or Macrophage. Id. ¶ 71. Plaintiff alleges that Goldberg’s opening of the Secret Account, without

providing the control agreements, caused Plaintiff to be in default under the CRG Loan Agreement and ultimately resulted in CRG obtaining summary judgment against Navidea. Id. ¶¶ 74, 82, 85, 86. i. Applicable Law New York choice of law rules dictate that the law of the state of incorporation governs claims for breach of fiduciary duty. Walton v. Morgan Stanley & Co.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

City of Los Angeles v. Lyons
461 U.S. 95 (Supreme Court, 1983)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Marcavage v. City of New York
689 F.3d 98 (Second Circuit, 2012)
Premium Mortgage Corp. v. Equifax, Inc.
583 F.3d 103 (Second Circuit, 2009)
ICD Holdings S.A. v. Frankel
976 F. Supp. 234 (S.D. New York, 1997)
CIBC Bank & Trust Co. v. Banco Central Do Brasil
886 F. Supp. 1105 (S.D. New York, 1995)
National Westminster Bank, U.S.A. v. Ross
130 B.R. 656 (S.D. New York, 1991)
VTech Holdings Ltd. v. Lucent Technologies, Inc.
172 F. Supp. 2d 435 (S.D. New York, 2001)
Air Atlanta Aero Engineering Ltd. v. SP Aircraft Owner I, LLC
637 F. Supp. 2d 185 (S.D. New York, 2009)
Granite Partners, LP v. Bear, Stearns & Co. Inc.
17 F. Supp. 2d 275 (S.D. New York, 1998)
Sabetay v. Sterling Drug, Inc.
506 N.E.2d 919 (New York Court of Appeals, 1987)
Brown v. Daikin America Inc.
756 F.3d 219 (Second Circuit, 2014)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
IN RE: NAVIDEA BIOPHARMACEUTICALS LITIGATION, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-navidea-biopharmaceuticals-litigation-nysd-2019.